for many years. Diabetes-related tickers: ( JNJ +0.4% )( OTCQB:ISLT )( OTCQB:BTHE +20% )( VTAE +2.5% )( NVO +0.5% )( MRK +0.9% )(NASDAQ: VKTX )( HPTX +0.4% )( ABT +1.2% )( OTCPK:TKPHF )( OTCPK:TKPYY -0
VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players looking to enter the space are Novo Nordisk (NYSE: NVO ) and Zafgen (NASDAQ: ZFGN ). All will have a presence at Obesity Complete Story »
By Trevor Lowenthal : China Biologic Products (NASDAQ: CBPO ) is a biopharmaceutical company focused on marketing plasma-based products to China. China Biologic has displayed strong successive earnings growth over the past two quarters as it continues to bear the fruits from its efforts to raise ...
The European Commission approves Novo Nordisk's (NYSE: NVO ) Xultophy for the treatment of adult patients with type 2 diabetes to improve glycemic control in combination with oral glucose-lowering
In a Phase 3b clinical trial , Novo Nordisk's (NYSE: NVO ) Ryzodeg (insulin degludec/insulin aspart) administered twice daily provided successful glycemic control with fewer injections
By Investing Tricks : Sanofi's (NYSE: SNY ) revenues are distributed through three major segments and a large chunk is attributable to the pharmaceutical segment; 85% of revenues are attributed to the pharmaceutical segment. More than half the pharmaceutical revenues are drawn from the US and ...
By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for their obesity drug Contrave on September 10th, 2014. The FDA has finally determined that Contrave is a safe obesity drug to give to patients to help reduce their weight. Orexigen Therapeutics has been struggling to
By Sharon di Stefano : Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE: LLY ) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an ...
By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee concludes that Novo Nordisk's ( NVO +1.8% ) obesity drug Saxenda (liraglutide) is safe and effective enough to warrant approval . Post your comment!